Contacts
Senseonics Investor Relations Contact:
Philip Taylor
Investor Relations
415-937-5406
Investors@senseonics.com
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY.
Management is scheduled to present on Friday, June 9, 2023, from 9:30am to 9:55am ET. Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230526005019/en/
Related news for (SENS)
- Breaking News: MoBot’s Latest Update as of 09/03/25 07:00 PM
- Today’s Top Performers: MoBot’s Market Review 09/03/25 06:00 PM
- Today’s Top Performers: MoBot’s Market Review 09/03/25 05:00 PM
- Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters’ Option to Purchase Additional Shares, and Closing of Private Placement
- MoBot alert highlights: NASDAQ: CRSR, NASDAQ: RSLS, NYSE: SENS, NASDAQ: PRCH, NASDAQ: BLIV (04/09/25 04:00 PM)